Allogene Therapeutics ALLO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -52.3%+7.3pp | -53.4%+1.7pp | -54.4%-0.2pp | -55.1%-5.9pp | -59.6%-4.1pp | |
| Return on assets | -38.4%+7.7pp | -39.6%+3.7pp | -41.2%+2.3pp | -42.4%-3.0pp | -46.1%-2.4pp | |
| Return on invested capital | -51.3%+7.3pp | -56.5%+1.6pp | -53.7%+0.8pp | -63.8%-5.0pp | -58.6%-2.7pp | |
| Liquidity | ||||||
| Current ratio | 9.6×-0.1× | 7.9×-0.6× | 8.2×-1.2× | 8.9×-3.3× | 9.7×-3.1× | |
| Quick ratio | 9.6×-0.1× | 7.9×-0.6× | 8.2×-1.2× | 8.9×-3.3× | 9.7×-3.1× | |
| Cash ratio | 1.4×-0.3× | 1.9×-0.5× | 1.5×-0.4× | 2×-2.9× | 1.8×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.3×+0.1× | 0.3×+0.1× | 0.3×+0.1× | 0.3×+0.1× | 0.2×0.0× | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Interest coverage | -155.3×+657× | -194.7×+1,315× | -269.8×+2,708× | -424.5×— | -812.3×-733× | |
| Per Share | ||||||
| Book value per share | $1.16-35.1% | $1.33-38.8% | $1.42-35.9% | $1.57-41.9% | $1.79-34.4% | |
| Valuation | ||||||
| Market capitalization | $711.02M+164% | $307.88M-31.1% | $275.13M-53.0% | $273.41M-43.8% | $317.21M-58.0% | |
| Enterprise value | $751.47M+146% | $329.15M-27.2% | $312.17M-49.4% | $297.79M-25.5% | $353.38M-55.3% | |
| Price / book | 2.5×+1.9× | 1.1×0.0× | 0.9×-0.4× | 0.8×-0.2× | 0.8×-0.8× | |
| Free cash flow yield | -15.4%+58.2pp | -48.6%-3.6pp | -57.8%-20.6pp | -63.5%-16.4pp | -62.5%-32.4pp | |
| Earnings yield | -24.4%+69.3pp | -62%-4.3pp | -77.1%-28.7pp | -86.6%-29.2pp | -79.5%-40.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Allogene Therapeutics's ratios come from?
- Every ratio is computed from Allogene Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.